
DPYD Testing Gains Ground: NCCN Guideline Update Reflects Decades of Work Toward Safer Chemotherapy
In 1988, a quiet but seismic shift began in oncology. Researchers described how inherited dihydropyrimidine dehydrogenase (DPD) deficiency could cause catastrophic reactions to fluoropyrimidines such as 5-fluorouracil (5-FU)—a mainstay in the treatment of …